CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling

[1]  B. Goh,et al.  The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy , 2020, Medicinal research reviews.

[2]  C. Rüegg,et al.  The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication , 2020, International Journal of Molecular Sciences.

[3]  J. Aparicio,et al.  Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease , 2020, Journal of clinical medicine.

[4]  Shi-Yong Sun.  mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why? , 2020, Frontiers of Medicine.

[5]  O. Moaven,et al.  Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment , 2020, Cancers.

[6]  Jing Huang.  Current developments of targeting the p53 signaling pathway for cancer treatment. , 2020, Pharmacology & therapeutics.

[7]  Yang Liu,et al.  NRF2 in human neoplasm: Cancer biology and potential therapeutic target. , 2020, Pharmacology & therapeutics.

[8]  A. Kaser,et al.  Activating Transcription Factor 6 Mediates Inflammatory Signals in Intestinal Epithelial Cells Upon Endoplasmic Reticulum Stress. , 2020, Gastroenterology.

[9]  J. Tapia,et al.  Protein Kinase CK2 in Cancer Energetics , 2020, Frontiers in Oncology.

[10]  D. Calvisi,et al.  Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies , 2020, Hepatology.

[11]  A. Jemal,et al.  Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[12]  A. Basu,et al.  Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer , 2020, International journal of molecular sciences.

[13]  Xiang Hu,et al.  Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma , 2020, EBioMedicine.

[14]  Qifeng Yang,et al.  Huaier Suppresses Breast Cancer Progression via linc00339/miR-4656/CSNK2B Signaling Pathway , 2019, Front. Oncol..

[15]  A. K. Murugan.  mTOR: Role in cancer, metastasis and drug resistance. , 2019, Seminars in cancer biology.

[16]  A. Avan,et al.  AMP‐kinase inhibitor dorsomorphin reduces the proliferation and migration behavior of colorectal cancer cells by targeting the AKT/mTOR pathway , 2019, IUBMB life.

[17]  A. Aplin,et al.  Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment , 2018, Clinical Cancer Research.

[18]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[19]  O. Filhol,et al.  Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity , 2015, Cellular and Molecular Life Sciences.

[20]  J. Vázquez-Prado,et al.  mTORC1‐ and mTORC2‐interacting proteins keep their multifunctional partners focused , 2011, IUBMB life.

[21]  N. Eritja,et al.  CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. , 2009, The American journal of pathology.

[22]  T. Wandless,et al.  The Rapamycin-binding Domain of the Protein Kinase Mammalian Target of Rapamycin Is a Destabilizing Domain* , 2007, Journal of Biological Chemistry.

[23]  D. Litchfield.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. , 2003, The Biochemical journal.

[24]  O. Issinger,et al.  Protein kinase CK2 and its role in cellular proliferation, development and pathology , 1999, Electrophoresis.

[25]  G. Peters,et al.  Cyclin D1 as a cellular proto-oncogene. , 1995, Seminars in cancer biology.

[26]  M. Czech,et al.  Cloning and characterization of a cDNA encoding the beta subunit of human casein kinase II. , 1989, Biochemistry.